



JC03 Rec'd PCT/TT 25 JUL 2001

FORM PTO-1390

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No.

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**2577-115

U.S. Application No. (if known, see 37 CFR 1.5)

09/889926

INTERNATIONAL APPLICATION NO.

PCT/SG99/00011

INTERNATIONAL FILING DATE

11 February 1999

PRIORITY DATE CLAIMED

11 February 1999

TITLE OF INVENTION: NAC1 - A PLANT GENE ENCODING A TRANSCRIPTION FACTOR INVOLVED IN COTYLEDON AND LATERAL ROOT DEVELOPMENT**APPLICANT(S) FOR DO/EO/US:** Qi XIE and Nam-Hai CHUA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

ITEMS 11. TO 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: A courtesy copy of the International Application w/drawings and International Search Report.

U.S. APPLICATION NO. (If known) 09/889926

INTERNATIONAL APPLICATION NO.
PCT/SG99/00011ATTORNEY DOCKET NO.
2577-11517. ☒ [X] The following fees are submitted:**Basic National Fee (37 CFR 1.492)(a)(1)-(5):**

Search Report has been prepared by the EPO or JPO	\$ 860.00
International preliminary examination fee paid to USPTO (37 CFR 1.482)	\$ 690.00
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))	\$ 710.00
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$ 1,000.00
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)	\$ 100.00

CALCULATIONSPTO USE ONLY**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$ 860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [X] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

Claims	Number Filed	Number Extra	Rate
Total Claims	19 - 20 =	0	X \$18.00
Independent Claims	3 - 3 =	0	X \$80.00
Multiple dependent claim(s) (if applicable)			+ \$270.00

\$

TOTAL OF ABOVE CALCULATIONS =

\$ 000.00

Reduction by 1/2 for filing by small entity, if applicable. Applicant claims small entity status. See 37 C.F.R. §1.27.

\$

SUBTOTAL =

\$ 860.00

Processing fee of \$130.00 for furnishing the English translation later [] 20 [] 30 than months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

+

\$

TOTAL FEES ENCLOSED =

\$ 860.00

Amount to be
refunded

\$

charged

\$

- a. ☒ A check in the amount of \$860.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. 02-2135 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2135. A duplicate copy of this sheet is enclosed.
- d. ☐ Payment by credit card. (Form PTO-2038 enclosed.)

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Stephen A. Saxe
 Rothwell, Figg, Ernst & Manbeck
 555 13th St., N.W.
 Washington, D.C. 20004
 Phone: 202/783-6040

Signature

Stephen A. Saxe

Name

38,609

Registration Number

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	<i>Application Number</i>	PCT/SG99/00011
	<i>Filing Date</i>	Herewith
	<i>First Named Inventor</i>	Qi XIE
	<i>Group Art Unit</i>	Not Yet Assigned
	<i>Examiner Name</i>	Not Yet Assigned
	<i>Attorney Docket Number</i>	2577-115
<i>Title of the Invention:</i> NAC1 - A PLANT GENE ENCODING A TRANSCRIPTION FACTOR INVOLVED IN COTYLEDON AND LATERAL ROOT DEVELOPMENT		

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to examination on the merits, please amend the above-identified application as summarized below.

Delete the first full paragraph under "SUMMARY OF THE INVENTION" beginning at the bottom of page 1 and continuing on page 2 of the specification and substitute it with the replacement paragraph contained on the following page.

Amend claims 1, 3, 5 and 6 as shown on the following pages.

A marked-up copy of the original text of the amended claims and specification portion are attached to this amendment. Material inserted is indicated by underlining and material deleted is indicated by square brackets.

Clean Copy of Substitute Paragraph, beginning at the bottom of Page 1 and ending on Page 2:

A new Arabidopsis NAC family member, NAC1, is described. This gene was originally isolated by the ability of its cDNAs to alter yeast *S. pombe* cell morphology when overexpressed by using the method of Xia et al. (1996). Northern analysis showed that NAC1 was expressed in a tissue-specific manner with high levels in root and low levels in leaves. Whole-mount *in situ* experiments showed expression in actively dividing root and shoot meristems.

Clean Copy of Amended Claims 1, 3, 5 and 6:

1. (Amended) An isolated nucleic acid comprising bases 89-1060 of SEQ ID NO:1.
3. (Amended) An isolated protein at least 70% homologous to said protein of claim 2, wherein said isolated protein is a functional homologue of NAC1.
5. (Amended) A transgenic plant which is transgenic for a nucleic acid comprising the nucleic acid of claim 4.
6. (Amended) A transgenic plant cell which is transgenic for a nucleic acid comprising the nucleic acid of claim 4.

REMARKS

The amendments made herein were previously made via Article 34 Amendments during the PCT stage of this 35 U.S.C. § 371 filed application. This Preliminary Amendment is submitted with the belief that the Article 34 Amendments have not already been made for this application.

The amendment to the paragraph on pages 2-3 is to make clear that the reference to Xia et al. is an indication that the gene was isolated by using a method as taught by Xia et al. and to make clear that the Xia et al. reference does not itself teach the isolation of the NAC1 gene.

The changes to the claims were to make the claims more specific as to what is being claimed. It is urged that the amendments insert no new matter.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Stephen A. Saxe, Reg. No. 38,609				
SIGNATURE	<i>Stephen A. Saxe</i>			DATE	<i>July 25, 2001</i>
Address	Rothwell, Figg, Ernst & Manbeck Suite 701-East, 555 13th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

Attachments: Marked-Up Copy of Amendments

Substitute Paragraph, beginning at the bottom of Page 1 and ending on Page 2: Version with markings to show changes made

A new Arabidopsis NAC family member, NAC1, is described. This gene was originally isolated by the ability of its cDNAs to alter yeast *S. pombe* cell morphology when overexpressed by using the method of Xia et al. (1996) [(Xia et al., 1996)]. Northern analysis showed that NAC1 was expressed in a tissue-specific manner with high levels in root and low levels in leaves. Whole-mount *in situ* experiments showed expression in actively dividing root and shoot meristems.

Amended Claims 1, 3, 5 and 6: Version with markings to show changes made

1. (Amended) [A] An isolated nucleic acid comprising bases 89-1060 of SEQ ID NO:1.
3. (Amended) An isolated protein at least 70% homologous to said protein of claim 2, wherein said isolated protein is a functional homologue of NAC1.
5. (Amended) A transgenic plant which is transgenic for a nucleic acid comprising the nucleic acid of claim 4.
6. (Amended) A transgenic plant cell which is transgenic for a nucleic acid comprising the nucleic acid of claim 4.

09/889926 #3

2577-115
SAS:lew

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
) **Box PCT**
Qi XIE et al.)
)
Serial No. 09/889,926 of) Examiner: Not Yet Assigned
PCT/SG99/00011)
Filed: Feb. 11, 1999) Group Art Unit: Not Yet Assigned
)
For: NAC1-A PLANT GENE ENCODING A TRANSCRIPTION
FACTOR INVOLVED IN COTYLEDON AND LATERAL
ROOT DEVELOPMENT

SUBMISSION OF FORMAL DRAWINGS

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Attached hereto are eight (8) sheets of formal drawings to
replace the eight (8) sheets of informal drawings filed with the
subject application.

Respectfully submitted,

By Stephen A. Saxe
Stephen A. Saxe, Ph.D.
Attorney for Applicants
Registration No. 38,609
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 701-E, 555 13th Street, N.W.
Washington, D.C. 20004
Telephone: (202) 783-6040

Enclosures

09/889926-0500




FIG. 1




FIG. 2A




FIG. 2B



FIG. 2C



FIG. 2D




FIG. 2E



FIG. 2F



FIG. 2G

09/889 926 09/1999




FIG. 3A




FIG. 3B




FIG. 3C

09/889 926




FIG. 4A




FIG. 4B

pGB	pGA	INTERACTION
1-324	1-324	+
1-199	1-324	+
1-199	1-199	+
1-199	1-142	-
1-199	143-324	-

FIG. 4C




FIG. 5

-DEX

WT




FIG. 6A

+DEX

WT



FIG. 6B

-DEX

OVEREXPRESS



FIG. 6C

+DEX

OVEREXPRESS



FIG. 6D




FIG. 7A




FIG. 7D



FIG. 7G




FIG. 7B



FIG. 7E




FIG. 7C



FIG. 7F

FIG. 7A



FIG. 8A



FIG. 8B




FIG. 8C



FIG. 8D

09/889926

#3

2577-115

SAS:lew

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)

) **Box PCT**

Qi XIE et al.)

Serial No. 09/889,926)

(of PCT/SG99/00011))

Filed: February 11, 1999)

For: *NAC1* - A PLANT GENE ENCODING A TRANSCRIPTION FACTOR
INVOLVED IN COTYLEDON AND LATERAL ROOT DEVELOPMENT**STATEMENT PURSUANT TO 37 C.F.R. § 1.821(f)**

Box PCT

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

In the matter of the above-identified application, Applicants submit a computer readable form (computer diskette) containing the sequences of the application together with a paper copy of the sequence listing. It is hereby certified that the information recorded in computer readable form is identical to the paper copy of the sequence listing and includes no new matter. This Sequence Listing is identical to the one submitted for the PCT application and it is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the present application.

Respectfully submitted,



Stephen A. Saxe, Ph.D.

Attorney for Applicants

Registration No. 38,609

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 701-E, 555 13th Street, N.W.

Washington, D.C. 20004

Telephone: (202)783-6040

Enclosures

09/889926-094001

SEQUENCE LISTING

<110> Xie, Qi
Chua, Nam-Hai
Institute of Molecular Agrobiolology, The National U

<120> NAC1 - A PLANT GENE ENCODING A TRANSCRIPTION FACTOR
INVOLVED IN COTYLEDON AND LATERAL ROOT DEVELOPMENT

<130> 2248-115

<140> Not yet assigned

<141> 1999-02-11

<160> 2

<170> PatentIn Ver. 2.0

<210> 1
<211> 1287
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (89)..(1060)

<400> 1
gtcgcaccacg cctccgtctt tatctctctt ttctctttaa ccattccacta atcaaact 60
aaaacctaga aaaaaaaagg atcaaact atg gag acg gaa gaa gag atg aag 112
Met Glu Thr Glu Glu Glu Met Lys
1 5
gaa agt agt ata agc atg gtg gag gca aag ttg cct ccg gga ttc aga 160
Glu Ser Ser Ile Ser Met Val Glu Ala Lys Leu Pro Pro Gly Phe Arg
10 15 20
ttt cac ccg aag gac gat gag ctt gtc tgc gat tac ttg atg aga cga 208
Phe His Pro Lys Asp Asp Glu Leu Val Cys Asp Tyr Leu Met Arg Arg
25 30 35 40
tcg ctt cac aat aat cat cga cca cct ctt gtc ctg atc caa gtc gat 256
Ser Leu His Asn Asn His Arg Pro Pro Leu Val Leu Ile Gln Val Asp
45 50 55
ctc aac aag tgt gag cct tgg gac atc cca aaa atg gca tgc gtg gga 304
Leu Asn Lys Cys Glu Pro Trp Asp Ile Pro Lys Met Ala Cys Val Gly
60 65 70
ggg aag gat tgg tat ttc tac agc caa aga gac cga aaa tac gcg acg 352
Gly Lys Asp Trp Tyr Phe Tyr Ser Gln Arg Asp Arg Lys Tyr Ala Thr
75 80 85

ggg	ctg	aga	act	aac	cga	gca	acg	gcc	acc	gga	tat	tgg	aaa	gcc	acc	400
Gly	Leu	Arg	Thr	Asn	Arg	Ala	Thr	Ala	Thr	Gly	Tyr	Trp	Lys	Ala	Thr	
	90					95					100					
ggc	aaa	gac	aga	acc	att	cta	aga	aag	ggt	aag	cta	gtt	ggg	atg	agg	448
Gly	Lys	Asp	Arg	Thr	Ile	Leu	Arg	Lys	Gly	Lys	Leu	Val	Gly	Met	Arg	
105					110					115					120	
aag	aca	ttg	gtt	ttc	tat	caa	ggt	cga	gct	cct	cga	ggc	cgt	aaa	acc	496
Lys	Thr	Leu	Val	Phe	Tyr	Gln	Gly	Arg	Ala	Pro	Arg	Gly	Arg	Lys	Thr	
				125					130					135		
gat	tgg	gtc	atg	cac	gaa	ttc	cgt	ctc	caa	gga	tct	cat	cat	cct	ccc	544
Asp	Trp	Val	Met	His	Glu	Phe	Arg	Leu	Gln	Gly	Ser	His	His	Pro	Pro	
		140						145					150			
aat	cat	tct	ctg	agc	tct	cca	aag	gaa	gac	tgg	gtc	ttg	tgt	agg	gta	592
Asn	His	Ser	Leu	Ser	Ser	Pro	Lys	Glu	Asp	Trp	Val	Leu	Cys	Arg	Val	
		155					160					165				
ttc	cat	aag	aat	acg	gaa	gga	gtt	ata	tgt	aga	gac	aac	atg	gga	agc	640
Phe	His	Lys	Asn	Thr	Glu	Gly	Val	Ile	Cys	Arg	Asp	Asn	Met	Gly	Ser	
	170					175					180					
tgt	ttt	gat	gag	aca	gcc	tct	gca	tcg	ctt	cct	cca	ctg	atg	gat	cct	688
Cys	Phe	Asp	Glu	Thr	Ala	Ser	Ala	Ser	Leu	Pro	Pro	Leu	Met	Asp	Pro	
185					190					195					200	
tac	atc	aac	ttt	gac	caa	gaa	ccc	tct	tct	tat	ctc	agt	gat	gat	cat	736
Tyr	Ile	Asn	Phe	Asp	Gln	Glu	Pro	Ser	Ser	Tyr	Leu	Ser	Asp	Asp	His	
				205					210					215		
cac	tac	atc	atc	aat	gag	cac	gta	ccc	tgc	ttc	tcc	aat	ttg	tca	cag	784
His	Tyr	Ile	Ile	Asn	Glu	His	Val	Pro	Cys	Phe	Ser	Asn	Leu	Ser	Gln	
			220					225					230			
aac	caa	acc	tta	aac	tcg	aac	cta	acc	aac	tca	gtc	tct	gaa	ctc	aag	832
Asn	Gln	Thr	Leu	Asn	Ser	Asn	Leu	Thr	Asn	Ser	Val	Ser	Glu	Leu	Lys	
		235					240					245				
att	cca	tgc	aag	aac	cct	aac	ccc	ttg	ttt	act	ggt	ggt	tca	gcc	tca	880
Ile	Pro	Cys	Lys	Asn	Pro	Asn	Pro	Leu	Phe	Thr	Gly	Gly	Ser	Ala	Ser	
	250					255					260					
gcc	acg	ctc	aca	ggc	ctc	gac	tca	ttc	tgt	tct	tca	gat	cag	atg	gtt	928
Ala	Thr	Leu	Thr	Gly	Leu	Asp	Ser	Phe	Cys	Ser	Ser	Asp	Gln	Met	Val	
265					270					275					280	
ctc	aga	gct	cta	ctc	agt	cag	ctc	act	aag	att	gat	gga	agc	ctc	ggg	976
Leu	Arg	Ala	Leu	Leu	Ser	Gln	Leu	Thr	Lys	Ile	Asp	Gly	Ser	Leu	Gly	
				285					290					295		
cct	aaa	gaa	tca	cag	agt	tat	gga	gaa	ggt	agc	tcg	gag	agc	ctc	ctg	1024
Pro	Lys	Glu	Ser	Gln	Ser	Tyr	Gly	Glu	Gly	Ser	Ser	Glu	Ser	Leu	Leu	
			300					305						310		

acc gac atc ggt att cca agc act gtt tgg aat tgc tgatgatcga 1070
 Thr Asp Ile Gly Ile Pro Ser Thr Val Trp Asn Cys
 315 320

gtgtaacgag agttactatt gctatatcc tatccatgat tggaacaatt cttcgggggg 1130
 aaataacgtg tgcttgtctg attgtacaaa catttctca ctcttgtacc cacggtagat 1190
 tcatgtaaaa taccacttat gacgctagac atacatatat ttcatcgtag ttccatttgt 1250
 ttcaaaaaaa aaaaaaaaaa aaaaaaaggg cggccgc 1287

<210> 2

<211> 324

<212> PRT

<213> Arabidopsis thaliana

<400> 2

Met Glu Thr Glu Glu Glu Met Lys Glu Ser Ser Ile Ser Met Val Glu
 1 5 10 15

Ala Lys Leu Pro Pro Gly Phe Arg Phe His Pro Lys Asp Asp Glu Leu
 20 25 30

Val Cys Asp Tyr Leu Met Arg Arg Ser Leu His Asn Asn His Arg Pro
 35 40 45

Pro Leu Val Leu Ile Gln Val Asp Leu Asn Lys Cys Glu Pro Trp Asp
 50 55 60

Ile Pro Lys Met Ala Cys Val Gly Gly Lys Asp Trp Tyr Phe Tyr Ser
 65 70 75 80

Gln Arg Asp Arg Lys Tyr Ala Thr Gly Leu Arg Thr Asn Arg Ala Thr
 85 90 95

Ala Thr Gly Tyr Trp Lys Ala Thr Gly Lys Asp Arg Thr Ile Leu Arg
 100 105 110

Lys Gly Lys Leu Val Gly Met Arg Lys Thr Leu Val Phe Tyr Gln Gly
 115 120 125

Arg Ala Pro Arg Gly Arg Lys Thr Asp Trp Val Met His Glu Phe Arg
 130 135 140

Leu Gln Gly Ser His His Pro Pro Asn His Ser Leu Ser Ser Pro Lys
 145 150 155 160

Glu Asp Trp Val Leu Cys Arg Val Phe His Lys Asn Thr Glu Gly Val
 165 170 175

Ile Cys Arg Asp Asn Met Gly Ser Cys Phe Asp Glu Thr Ala Ser Ala
 180 185 190

09889926.091301

[illegible]

TITLE OF THE INVENTION

NAC1 - A PLANT GENE ENCODING A TRANSCRIPTION FACTOR INVOLVED IN COTYLEDON AND LATERAL ROOT DEVELOPMENT

BACKGROUND OF THE INVENTION

The NAC genes (including NAM, ATAF1, ATAF2 and CUC2) belong to a relatively large gene family found only in plants thus far. These genes encode proteins which are conserved in their N-terminal ~170 amino acids but are highly divergent in their C-termini. Previous genetic studies in petunia (Souer et al., 1996) and Arabidopsis (Aida et al., 1997) have suggested that some members of the NAC family play a role in patterning of the shoot and floral meristem.

Petunia embryos carrying the *no apical meristem* (*nam*) mutation fail to develop a shoot apical meristem. Occasional shoots on *nam* seedlings bear flowers that develop ten instead of five primordia in the second whorl. Double mutants with the homeotic gene *green petals* show that *nam* acts independently of organ identity in whorl 2 and also affects primordium number in whorl 3. Strikingly, *nam* mRNA accumulates in cells at the boundaries of meristems and primordia. It has been shown that *nam* plays a role in determining positions of meristems and primordia (Souer et al., 1996).

Mutations in *CUC1* and *CUC2* (for *CUP-SHAPED COTYLEDON*), which are genes of Arabidopsis, cause defects in the separation of cotyledons (embryonic organs), sepals, and stamens (floral organs) as well as in the formation of shoot apical meristems. These defects are most apparent in the double mutant. Phenotypes of the mutants suggest a common mechanism for separating adjacent organs within the same whorl in both embryos and flowers. The *CUC2* gene was cloned and found to encode a protein homologous to the petunia NAM protein (Aida et al., 1997).

The publications and other materials used herein to illuminate the background of the invention or provide additional details respecting the practice, are incorporated by reference, and for convenience are respectively grouped in the appended List of References.

SUMMARY OF THE INVENTION

A new Arabidopsis NAC family member, *NAC1*, is described. This gene was originally isolated by the ability of its cDNAs to alter yeast *S. pombe* cell morphology when

09/889926-0001

overexpressed (Xia et al., 1996). Northern analysis showed that NAC1 was expressed in a tissue-specific manner with high levels in root and low levels in leaves. Whole-mount *in situ* experiments showed expression in actively dividing root and shoot meristems.

NAC1 shares a high amino acid sequence homology with other members of the NAC gene products in the N-terminus. *In vitro* DNA binding studies utilizing a recombinant GST-NAC1 protein and different truncated NAC1 derivatives demonstrated an interaction between the -90 region of the 35S promoter and the conserved N-terminal domain of the protein. Interestingly, yeast assays show that the C-terminus of NAC1 fused to a GAL4 DNA-binding domain can activate transcription. Analysis of different deletion fusions showed that the transactivation domain is located in the C-terminus of the NAC1 protein. In addition, two-hybrid assays demonstrated that NAC1 can homodimerize and that the dimerization domain is located in the conserved N-terminal region of the protein. A 21 bp putative bipartite nuclear localization signal sequence was found in the N-terminal conserved NAC domain. Transgenic Arabidopsis were generated using a GFP-NAC1 fusion construct under the control of a dexamethasone (Dex) inducible promoter-GVG system. Analysis of transgenic lines expressing a GFP-NAC1 fusion protein under Dex induction condition revealed nuclear localization of the chimeric polypeptide *in vivo*. These data indicate that NAC1 belongs to a newly identified family of transcription factors.

One aspect of the invention is a transgenic plant comprising a gene which encodes NAC1 or a functionally equivalent protein (meaning a protein which binds to the same DNA binding site as does NAC1 and which is at least 70% identical with, preferably 80% identical with, more preferably 90% identical with, and most preferably at least 95% identical with NAC1) which causes the transgenic plant to grow larger than a nontransgenic plant. The plant may be larger because it is heavier, because it has bigger leaves, because it has thicker stems, because it has more roots, and/or because it has larger roots.

A second aspect of the invention is a gene encoding NAC1 or a functionally equivalent protein wherein plants which are transgenic for this gene grow larger than a nontransgenic plant.

A third aspect of the invention is NAC1 or a functionally equivalent protein wherein if a plant is made transgenic for a gene encoding NAC1 or said functionally equivalent protein said transgenic plant will grow larger than a plant which is not transgenic.

Another aspect of the invention is a transgenic plant cell which contains a gene encoding NAC1 or a functionally equivalent protein which causes the plant cell to grow larger than a nontransgenic cell.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Tissue specific expression of NAC1 gene. Autoradiography of RNA gel blots containing 10 μ g of total RNAs isolated from different tissues, as labeled. Seedlings were harvested from two weeks old plants. Cauline leaves (leaf), main and lateral stems (stem), flower clusters (flower), and siliques of different stages were harvested from 35 to 40 days old soil growth plants. Roots were taken from two weeks vertical growth seedlings on SM plate. The filter was hybridized with radiolabeled C-terminal of NAC1 and then reprobbed with the radiolabeled 18S rDNA probe as a loading control.

Figure 2. Whole mount *in situ* study of NAC1 in seedlings and flowers. Whole-mount *in situ* hybridization were performed in seedling and flower with a digoxigenin-labeled (DIG) C-terminal specific antisense probe (A, B, C, D and E) and with a DIG labeled sense probe (F and G). A and F are 12 days old seedlings. Root materials are from 12 day seedling and D is 7 day old seedling. Flowers were taken from 40 day old soil growth plants.

Figure 3. GST-NAC1 fusion protein binding to CaMV 35S promoter -90 region. (A) Affinity of GST-NAC1 fusion protein binding to 35S promoter -90 regions. Amount of proteins is as follows: Lane 1, 500 ng GST protein. Lanes 2 to 9 are NAC1 fusion proteins. Lanes 2 and 6, 10 ng; lanes 3 and 7, 100 ng; lanes 4 and 8, 250 ng; lanes 5 and 9, 500 ng. As the cold competitor, unlabeled same fragment of DNA was used. (B) Map of different deletions of NAC1 fusion to GST. (C) Different deletions of NAC1 fusion protein binding to -90 region of CaMV 35S promoter. 20 ng of each recombined protein was used.

Figure 4. Specific interaction between NAC1 and NAC1 in the yeast two-hybrid system assay. Yeast HF7c cells were co-transformed with plasmids expressing the GAL4^{BD} alone or GAL4^{BD}-NAC1 fusion and the plasmids expressing the GAL4^{AD} alone or fused to NAC1. (A) Cells were streaked on plates with or without histidine plus 10 mM 3-AT (Sigma)

according to the distribution shown in the center of picture. The ability to grow in the absence of histidine depends on the functional reconstitution of a GAL4 activity. (B) The map of different deletions of NAC1 protein fusion to pGA vector. (C) The ability of interaction between the different deletions of NAC1 versions in two-hybrid system assay.

Figure 5. Localization of transactivation domain in NAC1 protein. Different deletion version of NAC1 were cloned into Gal4 DNA binding vector and transformed into yeast strain is HF7c. Transformation mixture was plated on MM plates with histidine or without histidine supplement with necessary amino acids. The results were taken from three days growth plates.

Figure 6. Affect of overexpression of NAC1 in plants. (A) Wild-type plants grown in the absence of Dex. (B) Wild-type plants grown in the presence of Dex. (C) Transgenic plants grown in the absence of Dex. (D) Transgenic plants grown in the presence of Dex.

Figure 7. Cotyledon developmental changes in C-terminal specific antisense plants. SEM shows abaxial surface of cotyledon. A and D (detail) are wild-type, B and E (detail) are no severe phenotype, C and F, G (detail) are severe phenotype. Boxes with letters in A, B and C show the regions that are detailed.

Figure 8. Wild-type or transgenic plant seeds with antisense NAC1 were germinated on MS or MS plus Dex medium. (A) Wild-type in the absence of Dex; (B) wild-type induced with Dex; (C) transgenic in the absence of Dex; and (D) transgenic induced with Dex.

DETAILED DESCRIPTION OF THE INVENTION

The *nac1* gene was isolated in a project to isolate plant cytoskeletal, cell cycle-related and polarity-related proteins using *Schizosaccharomyces pombe*. An *A. thaliana* cDNA library under the control of the thiamine-repressible *nmt1* promoter of pREP5N was transformed into wild type *S. pombe* cells. One transformant showed elongated cells and multiseptimas when the promoter was depressed. A cDNA clone was isolated from this transformant and retransformed into *S. pombe* to confirm the cell shape change is due to

expression of the cDNA. The isolated cDNA (At012) encodes a single open reading frame (ORF) of 324 amino acids (SEQ ID NO:2). The putative protein sequence was searched against GenBank. A BLAST search indicated that the protein is novel. The N-terminus of the protein was found to contain a NAC domain, a domain found in members of the NAC gene family (NAM, ATAF1, ATAF2, CUC2). This domain covers the first 175 amino acids of the protein. The rest of the protein encoded by *nac1* has no high homology to any known sequence.

Homology, for polypeptides, is typically measured using sequence analysis software. See, e.g., the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 910 University Avenue, Madison, Wisconsin 53705. Protein analysis software matches similar sequences using measures of homology assigned to various substitutions, deletions and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

The NAC family of genes has been identified only in plants. These genes encode proteins which are highly conserved in the N-terminus but which vary in the rest of the protein. The first two members, ATAF1 and ATAF2, were from Arabidopsis and were isolated by their ability to activate the 35S cauliflower mosaic virus (CaMV) promoter in yeast (H. Hirt, GenBank Accession Numbers X74755 and X74756). SENU5 cDNA, isolated in studies of leaf senescence in tomato (GenBank Accession Number Z75524; John et al., 1997), and the NAM protein (Souer et al., 1996), the product of the petunia *nam* gene, are required for proper development of shoot apical meristems and have been proposed to determine meristem location. CUC2 (Aida et al., 1997) is a member of the NAM family and is an Arabidopsis homologue of NAM. The Arabidopsis NAP protein is also a member of the family (Sablowski and Meyerowitz, 1998). Finally, GRAB1 (GenBank Accession Number AJ010829) and GRAB2 (GenBank Accession Number AJ010830) are two more recently reported members of the NAC family. These are from wheat and can interact with wheat dwarf virus (WDV) RepA protein. The trans-overexpression of GRAB1 and GRAB2 genes under the control of 35S promoter can inhibit the WDV replication in wheat cell culture.

The work reported here details the NAC domain in five blocks based on the

conservation and the charge of each block. Sequence alignment of NAC1 protein with all these proteins revealed that NAC1 has similar features with other NAC family members which corresponds to the recently identified NAC domain.

The genomic structure of *nac1* was analyzed by comparing the genomic sequence with the cDNA sequence. The NAC1 gene is located on chromosome 1. It includes two introns in the N-terminal coding region. The first intron is 1215 base pairs and occurs within the codon for amino acid 67. The second intron is 102 base pairs and is located between codons for amino acids 160 and 161. A domain search was performed and led to the identification of a putative bipartite nuclear localization signal within the NAC domain of NAC1. This 21 amino acid signal sequence is located from amino acid 117 to 137 and was the first found in a member of the NAC family. Performing the same search with the other reported NAC family members failed to reveal a similar signal. NAC homologues were seen in a rice EST database but no homologues were seen in other organisms such as mammalian, *Drosophila* and yeast.

Developmental Regulation of the NAC1 Gene

To investigate the roles of the NAC1 gene during plant development, its expression pattern was analyzed by Northern analysis using a *nac1* specific probe. Because members of the NAC family are very conserved at the N-termini even at the DNA level, a C-terminal probe was used. 10 µg of total RNA from each tissue was used for hybridization. A relatively high level of expression of *nac1* RNA was detected in the roots (Figure 1). A lower expression was seen in two week old seedlings which contain all vegetative tissue. Very low expression was detected in material obtained from stems and leaves. No expression was detected in the mixed stages of siliques and mixed mature flower and inflorescence, even after a long exposure.

Whole-mount *in situ* studies of 7 day and 12 day plants were performed using both sense and antisense probes to C-terminal encoding region of the gene. *nac1* expression was seen in actively dividing roots and shoot apical meristems (Figure 2). Expression was especially high in the root tip dividing region (Figures 2A and 2B) and lateral root formation region (Figure 2C). A lower expression was detected in cotyledon and young leaf. These results all correspond to the Northern results. No clear specific hybridization was detected in

flower (Figure 2E). Also, no signal was detected in siliques and stems (data not shown). No specific signal was observed in seedlings hybridized with sense RNA probe (Figures 2F and 2G).

DNA Binding and DNA Binding Domains

The first two NAC family genes, ATAF1 and ATAF2, were cloned by their ability to activate a cauliflower mosaic virus (CaMV) 35 S promoter construct in yeast. These two proteins, as well as the other NAC family genes, are conserved in N-terminal NAC domain. The GRAB1 and GRAB2 proteins from wheat also bind to the 35S promoter -500 region. The CaMV 35S promoter contains several known DNA binding elements. A number of plant transcriptional factors have been identified as binding to different elements in the regulatory region of the promoter.

To test whether NAC1 protein could bind to the 35S promoter, the -90 region of the 35S promoter was first used as a probe. *nac1* was cloned into the GST fusion vector pGEX-4-2T and transformed into *E. coli*. The recombinant GST fusion protein was purified and an assay was performed to test for specific binding to DNA. Since a GST fusion protein was being assayed, GST itself was used as a control. GST had no ability to bind to the -90 region of the 35S promoter even when 500 ng of purified protein was used (see Figure 3A). Different amounts of purified GSTNAC1 protein were tested. Binding was detected with as little as 10 ng of protein and with only 4 hours of exposure of the film (Figure 3A). It must be noted that the purified GST protein contained only about 10% of intact GST fusion form. Most of the protein degraded during the bacterial growth and purification. This is because after IPTG is added to induce the protein expression, the bacteria can not grow well and the protein begins to degrade before the purification. The addition of excess cold 35S promoter competitor DNA abolished the formation of DNA-protein complex in a concentration-dependent manner (Figure 3A). These results demonstrate that NAC1 protein binds specifically to the -90 region of the 35S promoter.

Binding of NAC1 to an AS-1 element and a mutant form of the element, -83 to -63 of the 35S promoter, was also tested. Plant zip transcription factors have been identified as binding to this region. The binding affinity was reduced and no clear difference was found between the original AS-1 element and the mutated form. This result indicates that NAC1

had a different DNA binding site than bZIP transcriptional factors and the sequences around the AS-1 element are important for specific binding of NAC1.

To test the DNA binding domain of NAC1, different deletion forms of *nac1* were cloned in the GST fusion vector and the fusion proteins were isolated to test the DNA binding ability to the -90 region of the 35S promoter. 20 ng of each protein was used in this assay. The results are shown in Figure 3C. The truncated form GSTNAC1 contained the first 199 amino acids, the intact NAC domain. This maintained similar binding specific to the DNA probe. A truncated version containing only the first 3 intact blocks of the NAC domain and part of block IV lost the DNA binding ability. Similarly, the complementation of this deletion form, the rest of the protein containing part of block IV and intact block V does not bind to the DNA probe. Together these results indicate that the DNA binding domain is located in the NAC domain and that block IV is important for DNA binding and block V is not enough for DNA binding.

NAC1 Homodimers and the Dimerization Domain

Transcription factors usually form dimers when they bind to DNA. To determine whether NAC1 forms dimers, we used a two-hybrid technique. The method was efficiently used to test dimerization and to study the protein-protein interaction including dimerization. The intact NAC1 was fused to both a Gal4 DNA activation domain and a DNA binding domain and cotransformed into reporter yeast. A clear interaction was observed when NAC1 was expressed by both vectors. Yeast were able to grow in three days even when 10 mM 3-AT was applied to block the nonspecific interactions (Figure 4A). It must be mentioned that when NAC1 is expressed only in the DNA binding vector it can at a low level autoactivate the system so that the yeast can grow very slowly (Figure 4A).

To identify the region of NAC1 required for dimerization, we constructed a series of deletions and analyzed their ability to form complexes in yeast. First a deletion of the C-terminus was made from amino acid 200 through the end of the protein. This left a protein of the first 199 amino acids. This 199 amino acid protein fragment contains the intact NAC domain and it was able to form dimers with intact NAC1. This 199 amino acid version gave no background signal like the wild-type full length version of NAC1. Therefore the 199 amino acid version was used as the fixed partner to test other deletions. A variety of different

deletions in the activation domain vector were prepared (Figure 4B). When the same deletion (lack of sequence beyond amino acid 199) was prepared in pGA the interaction was as strong as with the intact protein. But when the deletion affected block IV of the NAC domain and the construct contained only the first three intact blocks of the NAC domain, formation of dimers was abolished (Figure 4C). Deletion of the N-terminus leaving only the latter half of block IV and intact block V resulted in a protein unable to form dimers. The data strongly support the conclusion that the NAM domain of NAC1 contains the dimerization domain. Block IV is important for dimer formation but block V itself is not enough to form a dimer. The NAC1 protein can form homodimers and this was confirmed by gel filtration. When bacteria expressed a protein of the first 199 amino acids of NAC1, the purified peptide including the complete NAC domain ran at twice the size in a native gel as in a denaturing gel.

Transactivation and the Transactivation Domain

In the yeast two-hybrid assay we found that NAC1 can auto-activate the system to a low level but the C-terminal deletion can not. Therefore we used a modified one-hybrid method with the hybrid transcription factor to identify the activation domain of the NAC1 gene. The vector pGBT8 which contains only the Gal4 DNA binding domain but no activation domain was used. Different deletions of the NAC1 gene were cloned into this plasmid in a fusion to the Gal4 DNA binding domain and the resulting plasmids were transformed into yeast containing UAS_{gal}-CYC1-HIS3 reporter gene. Selection was performed on histidine minus plates. If the part of the fusion protein contained activation activity, Gal4 transcription should be reconstructed and switch on the promoter of HIS3. With histidine synthesis, yeast can grow on medium without histidine. The Gal4 activation domain was used as the positive control and it gave full activity as shown in Figure 5. As mentioned above, the complete NAC1 protein gave only a low activation activity. The N-terminal fusion containing the first 132 amino acids or the first 199 amino acids gave no activity. Similarly, a fusion with a peptide fragment of amino acids 143-199 gave no activity. In contrast, a fusion containing amino acids 133 to the carboxy terminus fully activated the reporter gene giving a signal as strong as the positive control Gal 4 transcription factor. The use of a fusion containing only amino acids 143-269 also gave full activity. This is a highly

acidic amino acid region. The C-terminal fusion containing only the last 54 amino acids resulted in low activity. The results indicate that the activation domain of NAC1 is located in the C-terminus

Because the NAC family has been seen only in plants and not in other organisms, it was important to check the transactivation activity in plants. An *in vivo* experiment was devised to check the activation domain. Two plasmids were constructed. The first one carried the Gal4 DNA binding-MCS-Nos terminal cassette tagged with a CaMV 35S promoter. The tested gene can be cloned into MCS in frame with Gal4 DNA binding domain.

The other plasmid contains the reporter gene construct 6xUAS-TATA-Luc which can express luciferase if some proteins can bind to the 6xUAS element to activate the promoter. Co-bombardment with the two plasmids together at different combinations demonstrated the system is reproducible and applicable. We used the activation domain from virus VP16 as a positive control and it gave a very high activity. In contrast, neither the second plasmid (pTALuc) alone nor it plus the vector pGal gave significant luciferase activity. A similar result was obtained as that from the yeast system. The full transactivation activity was identified in the peptide of amino acids 143-269. The last 54 amino acids also gave the low activity. The N-terminus of NAC1 gave no activity nor did the vector control itself. Both in yeast and in plant systems, it has been demonstrated that NAC1 contains a transactivation domain and the region corresponding to this activity is between amino acids 142-269.

Transgenic Arabidopsis Plants which Overexpress and Underexpress NAC1

In this study, a glucocorticoid-inducible transgenic system was used as previously described (Aoyama and Chua, 1997). A glucocorticoid-regulated transcription factor is encoded by a GVG whose transcription is controlled by the CaMV 35S promoter. The transcription of transgene is controlled by the glucocorticoid-activated promoter (6XUAS_{gal4}).

The 1287 basepair complete NAC1 encoding cDNA (SEQ ID NO:1) was cloned into the binary plant transformation vector pTA7002 in both directions and separately transformed into *Arabidopsis thaliana* *lansberg* ecotype by a root transformation method. Overexpressing and underexpressing transgenic lines were selected from hygromycin containing medium. Six independent transgenic lines of overexpressing and 4 independent lines of underexpressing were selected. All of the lines segregated for one T-DNA locus according to

hygromycin resistant segregation ratios.

The six overexpressing transgenic plants were of three different phenotypes. Four of the lines were of one phenotype while the remaining two lines each showed a different phenotype. These latter two phenotypes are similar to antisense plants as will be described below. Studies of the first four lines of similar phenotype showed that those plants grow more quickly and grow larger than nontransgenic plants both under *in vitro* and in soil growth conditions. More lateral roots were produced when inducing conditions were employed, such as on plate vertical or in plantcon growths. Data is presented for *in vitro* growth conditions. Seedlings of different ages were transferred from MS medium to both MS medium and MS plus 10 μ M Dexamethasone (Dex), then checked after one week of growth. Ten plants of each homozygous line were weighed after cleaning the agar or soil off of the plants. One week old seedlings transferred to Dex medium were 1.1 to 1.3 times heavier than uninduced plants, 15 day seedlings were 1.3 to 1.8 times heavier, and 25 day old seedlings were 1.4 to 2.6 times heavier. The increased weight in the induced plants resulted from bigger leaves, thicker stems and more roots, with the leaf size being the major contributor. Leaf epidermal cells from different parts of plants were analyzed by scanning electron microscopy (SEM). SEM showed that the cell size of old leaves was bigger than control cell size while there was no clear difference in cell size of new growth leaves. Vertical growth roots of a representative line are shown in Figure 6. More and longer lateral roots were produced in Dex induced lines. Total RNA was prepared from 48 hour induced plants and mock controls and measured via Northern blots probed with the C-terminal specific probe for *nacl*. The results indicated that all four transgenic lines show that the transgene is expressed. The transgene mRNA size is larger than the native mRNA size and is easily distinguished.

The two remaining overexpression lines as well as all four selected lines of antisense transgenic plants showed some sharing of different combinations of phenotypes. One of the two overexpression lines and one of the antisense lines showed cotyledon curved-up phenotype in seedling stage. No clear phenotypes were detected in later vegetative inflorescence development stage. Two antisense lines showed very typical phenotypes in seedling stage as well as *cuc2* mutant. In this case, single, heart-shaped and fused cotyledon and more severe, rosette seedlings were detected at a low percentage around 7-10% of germination seedlings. Most of these seedlings, which cannot produce the shoot apical

meristem, died later.

One of the antisense lines and one overexpression line did not appear any different from uninduced plants during all seedling and vegetative growth stages. But at the stage of inflorescence development, floral organs were affected, particularly petals and stamens. The phenotypes were found in the first several flowers of the inflorescence. Those flowers have short petals and stamens, and in those with the more severe phenotypes the flower could not open at all. Some of them can open but clear short stamens can be seen. Those flowers were male and female-sterile. This kind of phenotype overlaps the overexpression of another Arabidopsis NAC family member - the NAP gene.

Transgenic Arabidopsis Plant Underexpression of C-terminal Specific NAC1 Gene

As members of the NAC gene family are highly conserved at the N-terminus, not only at the amino acid level but also at the nucleotide sequence level, antisense nucleic acids to this region will affect homologous genes as shown in petunia. Therefore, C-terminal specific antisense constructs were prepared using vector pTA7002 and transformed into Arabidopsis as described above. For this construct, we used the 0.6 kb *Bam*HI-*Not*I C-terminal fragment. Northern blots developed only one band corresponding to the NAC1 gene in all tissues when using this fragment as probe for the four of 6 homozygous lines we selected for analysis. All showed similar phenotypes, mainly affected cotyledon and root development. No clear phenotypes were detected during all other stages of plant growth. One representative line of the C-specific antisense plants is described here. Cotyledons of wildtype or uninduced seedlings showed a slight curved-down and smooth surface. In the first week of germination no clear phenotype was detected in cotyledon development, but in 10 day old seedlings, 20 to 25% show severe cotyledon curved-up phenotype. A few also showed a curved-back phenotype. The phenomenon can be easily detected under light microscopy or even seen directly by eye. At the later stage, black dots can be seen on the surface of cotyledons. The abaxial epidermal cells were checked by SEM and abnormal cell expansion was found over all cotyledon surfaces, although different levels of severity were seen (Figure 7). Those cells lost the normal puzzle-like structure and became disordered with different cell sizes and cell shapes (Figures 7C, 7F and 7G). Cotyledons of those 75 to 80% seedlings which showed no severe or clear curved-up phenotype under light microscopy also were checked by SEM.

SEM results indicated the surface cells of those cotyledons were also abnormal. Cells looked swollen and more expanded.

The root phenotypes were easily detected on vertical growth seedlings. Seeds were germinated on MS or MS plus Dex medium. After one week germination, seedlings were transferred to the same fresh medium and continuously grown for one week and then checked. A few roots were produced in seedlings which contained C-terminal antisense expression. Three lines had short or fewer lateral roots and one line almost had no lateral roots. Those seedlings which had short or fewer lateral roots were checked by microscope and it was found that the lateral roots can be initiated but cannot be elongated. Therefore the seedlings look as if they contain fewer roots in comparison to uninduced seedling (Figure 8). Similar results were obtained from liquid growth C-terminal antisense plants. One week old seedlings were added to liquid MS or MS plus Dex medium and after 12 days growth uninduced roots are larger than induced roots of seedlings.

The present invention is further detailed in the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below are utilized.

EXAMPLE 1

Plant Materials and Growth Conditions

Arabidopsis thaliana lansberg ecotype was used for the experiments. Seeds were surface sterilized with 20% bleach plus 0.01% Triton X-100 and washed three times with sterile water. After the final wash, 0.15% agarose was added to the seed and they were plated on MS or MS plus Dexamethasone (Dex) at different concentrations with 3% sucrose. Plates were incubated at 4°C for two days and transferred to a tissue culture room at 22°C under long day (16 hour light/8 hour dark) conditions. After two to three weeks, seedlings were potted in soil and grown in a growth chamber with a photoperiod of 16 hours light/8 hours dark at 22°C and 75% humidity.

For Dex treatment, dexamethasone (Sigma) was dissolved in DMSO to make 100 mM dexamethasone stock solution which was stored at -20°C. For *in vitro* growth plants, Dex was added to the plates at 0.1, 1 and 10 μ M. Dex was continually added to medium once a

week. Photocon and plantcon were used. Dex was first dissolved in sterile water at 1/25th volume of medium and then was added to the surface of the medium. For treatment of soil growth plants, Dex was added to sterile water containing 0.01% Triton X-100 at 30 μ M then sprayed to cover all surfaces of the plant, once every two days. For mock controls, sterile water containing 0.01% Triton X-100 was sprayed on the same number of plants.

Example 2

Transformation Constructs and Plant Transformation The binary transformation plasmid pTA7002 containing the complete two-component glucocorticoid-inducible system (Aoyama and Chua, 1997) was used as a vector. For overexpression and complete antisense constructs, a 1287 basepair *SalI*-*NotI* fragment containing the complete NAC1 encoding cDNA was blunt-ended and cloned into *XhoI* digested and calf intestinal alkaline phosphatase treated pTA7002 vector. To prepare a C-terminal specific antisense construct, the 605 basepair *BamHI*-*NotI* fragment containing C-terminal specific region of NAC1 encoding cDNA was blunt ended and cloned into pTA7002 vector as mentioned above. For transgenic constructs containing GFP-NAC1 fusion cassette, an *NaeI*-*SalI* fragment generated by PCR containing just NAC1 coding region was cloned into an intermediate GFP fusion vector pGFP2(GA)5II digested by *NaeI* and *SalI* to produce plasmid pGFPNAC1. Then the GFPNAC1 fusion was cut out by *XbaI* plus *PacI* and cloned into pTA7002 vector by using the same procedures as above. *Arabidopsis thaliana* lansberg roots were used as the plant material for transformation (Valvekens et al., 1988). T2 seeds were germinated on SM plates containing 20 μ g/mL hygromycin B to select resistant plants and transferred to soil to generate and to obtain homozygous T3 seeds. Two independent lines of homozygous T4 plants with a single insertion from each construct were used for detail analysis.

Example 3

Northern Analysis and Whole Mount *In Situ* Analysis

Total RNA was isolated from different tissues by using the Qiagen RNA preparation kit. Northern blot analysis was performed according to Nagy et al. (1988). For probes, a PCR fragment covered amino acids 200 to 324 was labeled with α - 32 P dCTP using a Redi-primed labeling kit (Amersham International). Whole plants or flowers were fixed for whole-

mount *in situ* hybridizations. Antisense RNA from the C-terminal specific region of NAC1 was labeled with digoxigenin UTP (Boehringer Biochemica, Mannheim, Germany). The hybridization was detected with anti-digoxigenin Fab fragment conjugated to alkaline phosphatase. As control probes, sense transcripts were prepared from the same clone using T3 transcriptase.

Example 4

Yeast Two-Hybrid Analysis

Two-hybrid analysis (Bartel et al., 1993; Fields and Song, 1989; Chevray and Nathans, 1992; Lee et al., 1995) was applied to dimerization analysis. The yeast strain HF7c (*MATa ura3-52 his3-200 ade2-101 lys2-801 trp1-901 leu2-3,112 gal4-542 gal 80-538 LYS2::GAL1UAS-GAL1TATA-HIS3 URA3::GAL417mers(x3)-CYC1TATA-LacZ* which contains the two reporter genes *LacZ* and *HIS3* was used. Yeast cotransformation with plasmids carrying the different Gal4 DNA binding domain and the Gal4 activation domain fusion was performed by methods known to those of skill in the art. See, e.g., Burke and Olson, 1986; Rudolph et al., 1985; Sakai et al., 1984. Other conditions have been described in detail elsewhere and are well known to those of skill in the art. To corroborate the interaction between the two fusion proteins, β -galactosidase activity was assayed by a replica filter assay.

Two versions of NAC1 were cloned into the Gal4 DNA binding domain vector pGBT8, a derivative of pGBT9 (Clontech) which contains a more versatile polylinker. Plasmid pGBNAC11-324 contains the complete open reading frame for NAC1 fused to the Gal4 DNA binding domain. Plasmid pGBNAC11-199 contains only the nucleic acid encoding the first 199 amino acids on the same vector. Different truncated versions of NAC1 were fused to the Gal4 activation domain vector pGAD424. Plasmid pGANAC11-324 contains the complete open reading frame for NAC1. Plasmid pGANAC11-199 contains nucleic acid encoding the first 199 amino acids of NAC1. Plasmid pGANAC11-142 contains nucleic acid encoding the first 142 amino acids of NAC1 and plasmid pGANAC1143-324 contains nucleic acid encoding amino acids from 143 to the C-terminus of the peptide.

Example 5

Transfection of Epidermal Cells by Particle Bombardment

Petals were cut into 2x2 cm pieces and put on a filter soaked with liquid MS medium. 2 μ g of each plasmid combination was used for each shoot in a vacuum of 27 inches of mercury using a helium pressure of 1100 psi. After bombardment plates were incubated in plant growth room overnight (16 hours) and 50 mM luciferin (Promega) was sprayed on the material. The results were checked after 10 minutes incubation.

Example 6

Production of GST-Fusion Proteins and DNA Binding

PCR product containing the complete coding region of NAC1 gene was cloned into pGEX-4-2T to produce pGST-NAC1 fusion construct. GST-NAC1 1-199 was generated by digesting pGST-NAC1 with *Bam*HI and *Sal*I and treated with Klenow and religated to produce pGST-NAC1 1-199 which contains only the first 199 amino acids of NAC1 protein. GST-NAC1 1-132 was obtained by cutting pGST-NAC1 with *Xho*I plus *Sal*I and religated. GST-NAC1 133-324 was constructed by cloning an *Xho*I-*Not*I fragment from the original cDNA clone into pGEX-4-2T. Plasmids were transformed into *E. coli* BL21(DE3). Transformants were grown to an OD₆₀₀ of 0.6 to 0.9 and then induced to express the fusion protein at 30°C for 4 hours by the addition of IPTG to 0.4 mM. Cells were washed once with PBS and resuspended in GST buffer (GCB: 50 mM Tris-HCl at pH 8.0, 200 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10 mM α -mercaptoethanol, 5 μ g/mL each of leupeptin, pepstatin and aprotinin, and 1 mM PMSF). Cells were lysed by sonication on ice (5x30 seconds), and the lysates were cleared by centrifugation (15 minutes at 12,000 rpm). The fusion protein was recovered by affinity chromatography on glutathione-Sepharose beads (Pharmacia). The DNA binding reaction contained 2×10^5 cpm DNA probe, 5 μ L of 4x reaction buffer (100 mM NaCl, 40 mM HEPES, pH 7.5, 2 mM EDTA, 20% glycerol, 140 mM α -mercaptoethanol), 0.5 μ g poly dIdC (Pharmacia), 1 μ L 1% Nonidet P40 and different amount of proteins in a total volume of 20 μ L. 10 μ L of reaction were used on a 4-6% 1/2 TBE native gel. A 100 basepair *Bam*HI fragment containing 35S -90 region was labeled by α -³²PdCTP in a Klenow labeling reaction.

details of preferred embodiments of the invention, it is to be understood that the disclosure is intended in an illustrative rather than in a limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, within the spirit of the invention and the scope of the appended claims.

LIST OF REFERENCES

- Aida M, et al. (1997). *The Plant Cell* 9:841-857.
- Aoyama T and Chua N-H. (1997). *Plant J.* 11:605-612.
- Bartel PL, et al. (1993). "Using the 2-hybrid system to detect protein-protein interactions." In Cellular Interactions in Development: A Practical Approach, Oxford University Press, pp. 153-179.
- Burke DT and Olson MV (1986). *DNA* 5:325-332.
- Chevray PM and Nathans DN (1992). *Proc. Natl. Acad. Sci. USA* 89:5789-5793.
- Fields S and Song O-K (1989). *Nature* 340:245-246.
- John I, et al. (1997). *Plant Mol. Biol.* 33:641-651.
- Lee JE, et al. (1995). *Science* 268:836-844.
- Nagy F, et al. (1988). In Plant Molecular biology Manual, B4 (Gelvin S and Schilperoort R, eds). Dordrecht, The Netherlands; Kluwer Academic Publishers, pp. 1-12.
- Rudolph H, et al. (1985). *Gene* 36:87-95.
- Sablowski RWM and Meyerowitz EM (1998). *Cell* 92:93-103.
- Sakai K, et al. (1984). *Mol. Cell. Biol.* 4:651-656.
- Souer E, et al. (1996). *Cell* 85:159-170.
- Valvekens D, et al. (1988). *Proc. Natl. Acad. Sci. USA* 85:5536-5540.
- Xia Q, et al. (1996). *Plant J.* 10:761-769.

ggg aag gat tgg tat ttc tac agc caa aga gac cga aaa tac gcg acg 352
Gly Lys Asp Trp Tyr Phe Tyr Ser Gln Arg Asp Arg Lys Tyr Ala Thr
75 80 85

ggg	ctg	aga	act	aac	cga	gca	acg	gcc	acc	gga	tat	tgg	aaa	gcc	acc	400
Gly	Leu	Arg	Thr	Asn	Arg	Ala	Thr	Ala	Thr	Gly	Tyr	Trp	Lys	Ala	Thr	
90						95				100						
ggc	aaa	gac	aga	acc	att	cta	aga	aag	ggt	aag	cta	gtt	ggg	atg	agg	448
Gly	Lys	Asp	Arg	Thr	Ile	Leu	Arg	Lys	Gly	Lys	Leu	Val	Gly	Met	Arg	
105					110					115					120	
aag	aca	ttg	gtt	ttc	tat	caa	ggt	cga	gct	cct	cga	ggc	cgt	aaa	acc	496
Lys	Thr	Leu	Val	Phe	Tyr	Gln	Gly	Arg	Ala	Pro	Arg	Gly	Arg	Lys	Thr	
				125					130					135		
gat	tgg	gtc	atg	cac	gaa	ttc	cgt	ctc	caa	gga	tct	cat	cat	cct	ccc	544
Asp	Trp	Val	Met	His	Glu	Phe	Arg	Leu	Gln	Gly	Ser	His	His	Pro	Pro	
				140				145					150			
aat	cat	tct	ctg	agc	tct	cca	aag	gaa	gac	tgg	gtc	ttg	tgt	agg	gta	592
Asn	His	Ser	Leu	Ser	Ser	Pro	Lys	Glu	Asp	Trp	Val	Leu	Cys	Arg	Val	
		155					160					165				
ttc	cat	aag	aat	acg	gaa	gga	gtt	ata	tgt	aga	gac	aac	atg	gga	agc	640
Phe	His	Lys	Asn	Thr	Glu	Gly	Val	Ile	Cys	Arg	Asp	Asn	Met	Gly	Ser	
		170				175					180					
tgt	ttt	gat	gag	aca	gcc	tct	gca	tcg	ctt	cct	cca	ctg	atg	gat	cct	688
Cys	Phe	Asp	Glu	Thr	Ala	Ser	Ala	Ser	Leu	Pro	Pro	Leu	Met	Asp	Pro	
185					190					195					200	
tac	atc	aac	ttt	gac	caa	gaa	ccc	tct	tct	tat	ctc	agt	gat	gat	cat	736
Tyr	Ile	Asn	Phe	Asp	Gln	Glu	Pro	Ser	Ser	Tyr	Leu	Ser	Asp	Asp	His	
				205					210					215		
cac	tac	atc	atc	aat	gag	cac	gta	ccc	tgc	ttc	tcc	aat	ttg	tca	cag	784
His	Tyr	Ile	Ile	Asn	Glu	His	Val	Pro	Cys	Phe	Ser	Asn	Leu	Ser	Gln	
				220				225					230			
aac	caa	acc	tta	aac	tcg	aac	cta	acc	aac	tca	gtc	tct	gaa	ctc	aag	832
Asn	Gln	Thr	Leu	Asn	Ser	Asn	Leu	Thr	Asn	Ser	Val	Ser	Glu	Leu	Lys	
		235					240					245				
att	cca	tgc	aag	aac	cct	aac	ccc	ttg	ttt	act	ggg	ggg	tca	gcc	tca	880
Ile	Pro	Cys	Lys	Asn	Pro	Asn	Pro	Leu	Phe	Thr	Gly	Gly	Ser	Ala	Ser	
	250					255					260					
gcc	acg	ctc	aca	ggc	ctc	gac	tca	ttc	tgt	tct	tca	gat	cag	atg	gtt	928
Ala	Thr	Leu	Thr	Gly	Leu	Asp	Ser	Phe	Cys	Ser	Ser	Asp	Gln	Met	Val	
265					270					275					280	
ctc	aga	gct	cta	ctc	agt	cag	ctc	act	aag	att	gat	gga	agc	ctc	ggg	976
Leu	Arg	Ala	Leu	Leu	Ser	Gln	Leu	Thr	Lys	Ile	Asp	Gly	Ser	Leu	Gly	
				285					290					295		
cct	aaa	gaa	tca	cag	agt	tat	gga	gaa	ggg	agc	tcg	gag	agc			

acc gac atc ggt att cca agc act gtt tgg aat tgc tgatgatcga 1070
 Thr Asp Ile Gly Ile Pro Ser Thr Val Trp Asn Cys
 315 320

gtgtaacgag agttactatt gctatatcc tatccatgat tggaacaatt ctccgggggg 1130
 aaataacgtg tgcttgtctg attgtacaaa catttccctca ctcttgtagc cacggtagat 1190
 tcatgtaaaa taccacttat gacgctagac atacatatat ttcatcgtag ttccatttgt 1250
 ttcaaaaaaaaa aaaaaaaaaa aaaaaaaggcg cgccgc 1287

<210> 2

<211> 324

<212> PRT

<213> Arabidopsis thaliana

<400> 2

Met Glu Thr Glu Glu Glu Met Lys Glu Ser Ser Ile Ser Met Val Glu
 1 5 10 15

Ala Lys Leu Pro Pro Gly Phe Arg Phe His Pro Lys Asp Asp Glu Leu
 20 25 30

Val Cys Asp Tyr Leu Met Arg Arg Ser Leu His Asn Asn His Arg Pro
 35 40 45

Pro Leu Val Leu Ile Gln Val Asp Leu Asn Lys Cys Glu Pro Trp Asp
 50 55 60

Ile Pro Lys Met Ala Cys Val Gly Gly Lys Asp Trp Tyr Phe Tyr Ser
 65 70 75 80

Gln Arg Asp Arg Lys Tyr Ala Thr Gly Leu Arg Thr Asn Arg Ala Thr
 85 90 95

Ala Thr Gly Tyr Trp Lys Ala Thr Gly Lys Asp Arg Thr Ile Leu Arg
 100 105 110

Lys Gly Lys Leu Val Gly Met Arg Lys Thr Leu Val Phe Tyr Gln Gly
 115 120 125

Arg Ala Pro Arg Gly Arg Lys Thr Asp Trp Val Met His Glu Phe Arg
 130 135 140

Leu Gln Gly Ser His His Pro Pro Asn His Ser Leu Ser Ser Pro Lys
 145 150 155 160

Glu Asp Trp Val Leu Cys Arg Val Phe His Lys Asn Thr Glu Gly Val
 165 170 175

Ile Cys Arg Asp Asn Met Gly Ser Cys Phe Asp Glu Thr Ala Ser Ala
 180 185 190

T00T60"926880

Ser Leu Pro Pro Leu Met Asp Pro Tyr Ile Asn Phe Asp Gln Glu Pro
195 200 205

Ser Ser Tyr Leu Ser Asp Asp His His Tyr Ile Ile Asn Glu His Val
210 215 220

Pro Cys Phe Ser Asn Leu Ser Gln Asn Gln Thr Leu Asn Ser Asn Leu
225 230 235 240

Thr Asn Ser Val Ser Glu Leu Lys Ile Pro Cys Lys Asn Pro Asn Pro
245 250 255

Leu Phe Thr Gly Gly Ser Ala Ser Ala Thr Leu Thr Gly Leu Asp Ser
260 265 270

Phe Cys Ser Ser Asp Gln Met Val Leu Arg Ala Leu Leu Ser Gln Leu
275 280 285

Thr Lys Ile Asp Gly Ser Leu Gly Pro Lys Glu Ser Gln Ser Tyr Gly
290 295 300

Glu Gly Ser Ser Glu Ser Leu Leu Thr Asp Ile Gly Ile Pro Ser Thr
305 310 315 320

Val Trp Asn Cys

WHAT IS CLAIMED IS:

1. A nucleic acid comprising bases 89-1060 of SEQ ID NO:1.
2. An isolated protein consisting of an amino acid sequence shown by SEQ ID NO:2.
3. An isolated protein at least 70% homologous to said protein of claim 2.
4. A nucleic acid encoding the protein of claim 3.
5. A transgenic plant comprising the nucleic acid of claim 4.
6. A transgenic plant cell comprising the nucleic acid of claim 4.
7. A method of growing a plant comprising transforming said plant with the nucleic acid of claim 4 and growing said plant wherein said plant will grow larger than a wild-type plant.
8. The method of claim 7 wherein said nucleic acid is controlled by a glucocorticoid activated promoter.
9. The method of claim 8 wherein said plant is treated with a glucocorticoid.
10. The method of claim 9 wherein said glucocorticoid is dexamethasone.
11. A method of growing a genetically altered plant larger than a wild-type version of said plant comprising overexpressing NAC1 in said altered plant.
12. The method of claim 11 wherein said plant produces larger leaves than said wild-type version.
13. The method of claim 11 wherein said plant produces larger roots than said wild-type version.
14. The method of claim 11 wherein said plant produces more lateral roots than said wild-type version.
15. A method of growing a genetically altered plant larger than a wild-type version of said plant comprising overexpressing a protein of claim 3 in said altered plant.
16. The method of claim 15 wherein said plant produces larger leaves than said wild-type version.
17. The method of claim 15 wherein said plant produces larger roots than said wild-type version.
18. The method of claim 15 wherein said plant produces more lateral roots than said wild-type version.
19. A transgenic plant made by inserting a nucleic acid of claim 4 into a wild-type plant.

1/8




Figure 1

09889926-091801






Figure 2

A



B



C






Figure 3

A



B



C

pGB	pGA	interaction
1-324	1-324	+
1-199	1-324	+
1-199	1-199	+
1-199	1-142	-
1-199	143-324	-

Figure 4

09/889926




Figure 5

6/8




Figure 6





Figure 7

8/8

-Dex

+Dex

WT



Antisense





Figure 8

DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) <input type="checkbox"/> Declaration Submitted with Initial Filing <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing	Attorney Docket No.	2577-115
	First Named Inventor	Qi XIE
	COMPLETE IF KNOWN	
	Application Number	PCT/SG99/00011
	Filing Date	11 February 1999
	Group Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: NAC1 - A PLANT GENE ENCODING A TRANSCRIPTIONAL FACTOR INVOLVED IN COTYLEDON AND LATERAL ROOT DEVELOPMENT, the specification of which was filed on 11 February 1999 as PCT International Application Number PCT/SG99/00011 and was amended on 25 July 2001.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.


Prior Foreign Application Numbers	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached? YES NO	
			<input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

I or we hereby appoint the registered practitioner(s) associated with Customer No. **6449** to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Direct all correspondence to Customer Number **6449**.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name: <u>Qi</u> (first and middle [if any])		Family Name: <u>XIE</u> or Surname	
Inventor's Signature 		Date <u>31/8/2001</u>	
Residence: City:	State	Country: Singapore	Citizenship: <u>Singapore</u> SGX
Mailing Address: <u>348K Pasir Panjang Road</u>			
Mailing Address			
City	State	Zip: 118824	Country: Singapore
NAME OF SECOND INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name: <u>Nam-Hai</u> (first and middle [if any])		Family Name: <u>CHUA</u> or Surname	
Inventor's Signature		Date	
Residence: City: <u>New York</u>	State: <u>New York</u>	Country: <u>U.S.</u>	Citizenship: <u>Singapore</u>
Mailing Address: <u>504 East 63rd Street, Apt. 16P</u>			
Mailing Address			
City: <u>New York</u>	State: <u>New York</u>	Zip: <u>10021</u>	Country: <u>U.S.</u>
NAME OF THIRD INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address			
Mailing Address			
City	State	Zip	Country
NAME OF FOURTH INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address			
Mailing Address			
City	State	Zip	Country

<p align="center">DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)</p> <p><input type="checkbox"/> Declaration Submitted with Initial Filing <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing</p>	Attorney Docket No.	2577-115
	First Named Inventor	Qi XIE
	COMPLETE IF KNOWN	
	Application Number	PCT/SG99/00011
	Filing Date	11 February 1999
	Group Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: NAC1 - A PLANT GENE ENCODING A TRANSCRIPTIONAL FACTOR INVOLVED IN COTYLEDON AND LATERAL ROOT DEVELOPMENT, the specification of which was filed on 11 February 1999 as PCT International Application Number PCT/SG99/00011 and was amended on 25 July 2001.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.


Prior Foreign Application Numbers	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
			<input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.


Application Number(s)	Filing Date (MM/DD/YYYY)

I or we hereby appoint the registered practitioner(s) associated with Customer No. **6449** to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Direct all correspondence to Customer Number **6449**.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name: Qi (first and middle [if any])		Family Name: XIE or Surname	
Inventor's Signature		Date	
Residence: City:	State	Country: Singapore	Citizenship: Singapore
Mailing Address: 348K Pasir Panjang Road			
Mailing Address			
City	State	Zip: 118824	Country: Singapore
NAME OF SECOND INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name: Nam-Hai (first and middle [if any])		Family Name: CHUA or Surname	
Inventor's Signature 		Date August 31, 01	
Residence: City: New York	State: New York	Country: U.S.	Citizenship: Singapore NY
Mailing Address: 504 East 63rd Street, Apt. 16P			
Mailing Address			
City: New York	State: New York	Zip: 10021	Country: U.S.
NAME OF THIRD INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address			
Mailing Address			
City	State	Zip	Country
NAME OF FOURTH INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address			
Mailing Address			
City	State	Zip	Country

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

✓ *Scanned copy is best available. Drawings are too dark.*